Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, L. S. Chan, S. Gu, Y. Bai, Z. Ren,X. Lin,Z. Chen, W. Jia, Y. Jin,Y. Guo, A. V. Sultanbaev, M. Pazgan-Simon, M. Pisetska, X. Liang,C. Chen, Z. Nie,L. Wang,A-L. Cheng, A. Kaseb,A. Vogel

ANNALS OF ONCOLOGY（2022）

引用 67|浏览0

暂无评分

摘要

The benefits of immunotherapy plus an anti-angiogenic TKI in uHCC are unclear. This study aimed to assess C (Camrelizumab; anti-PD-1 IgG4 monoclonal antibody) + R (Rivoceranib, Apatinib; VEGFR2-TKI) vs. S (Sorafenib) as first-line treatment for uHCC.

查看译文

关键词

unresectable hepatocellular carcinoma,sorafenib,rivoceranib,phase iii trial,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要